Enanta Pharmaceuticals, Inc. manufactures pharmaceutical products. The Company develops, produces, and markets antibacterial drugs for hepatitis C virus, respiratory tract infections, intravenous, and oral treatments for hospitals and communities. Enanta Pharmaceuticals offers its products throughout the United States.

Current Report (Form 8-K | Period ending 2024-12-09)

Annual Report (Form 10-K | Period ending 2024-09-30)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Enanta Pharmaceuticals (ENTA US)

Current Report (Form 8-K | Period ending 2024-12-09)

Annual Report (Form 10-K | Period ending 2024-09-30)

Current Report (Form 8-K | Period ending 2024-11-25)

Quarterly Report (Form 10-Q | Period ending 2024-06-30)

Current Report (Form 8-K | Period ending 2024-08-05)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)